The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ESMO WCGIC 2020 | Future approaches in esophageal cancer

Name: Future approaches in esophageal cancer
Uploaded: 2020-07-01T00:00:00Z
Duration: 1 min 28 s
Description: Omkara Veeranki, MD, University of Texas MD Anderson Cancer Center, Houston, TX, outlines future avenues in esophageal cancer treatment, including the approval of PD-L1 inhibitors for this indication as well as drawbacks to its use. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Omkara Veeranki • 1 Jul 2020

ESMO WCGIC 2020

Esophageal Cancer Gastrointestinal Cancer

Omkara Veeranki, MD, University of Texas MD Anderson Cancer Center, Houston, TX, outlines future avenues in esophageal cancer treatment, including the approval of PD-L1 inhibitors for this indication as well as drawbacks to its use. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).